TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04652271

Intervention type: PROCEDURE
Intervention: Pancreatic surgery
Description: Open, laparoscopic or robotic surgery of the pancreas
Study: NCT04864730

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05672342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delta-8-Tetrahydrocannabinol
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05686174

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MBS217
Description: Soybean Fermented Extract (MBS217)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Without active ingredient
Study: NCT04760665

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: Patients will receive four fecal microbiota transplantation (FMT) capsules. Microbiota is obtained from healthy patients.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive four oral capsules containing placebo. These capsules will have the same shape, weight and colour as capsules containing FMT.
Study: NCT06569992

Intervention type: OTHER
Intervention: VIS, TIES
Description: The vasopressor and inotropic drug dosages administered during the follow-up of these patients will be recorded, and the Vasoactive-Inotropic Score (VIS) and Total Inotrope Exposure Score (TIES) will be calculated.
Study: NCT05842187

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of tumor tissue for organoid culture
Description: By collecting fresh tumor tissues (including ascites, pleural effusion, biopsy tissues, palliative surgery specimens, etc.) and culturing them into organoids in vitro, this study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment, and the study aims to evaluate the clinical effectiveness of the drug and its consistency with in vitro organoid drug sensitivity.
Study: NCT06407310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: I.V Pembrolizumab (keytruda) 200 mg every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: I.V Carboplatin at AUC 1.5 weekly for a total of 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: I.V Paclitaxel at 80 mg/m2 weekly for a total of 12 weeks.
Study: NCT05407259

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: There will be four conditions (three exercises and one control) on visits 3-6. For the three exercise conditions, all training parameters except intensity will be the same. The sets in high, moderate, and low intensity correspond to the rate of perceived exertion (0-10 scale) 7-9, 5-6, and 3-4, respectively. Therefore, the participants will perform 5 repetitions barbell squat, barbell press, and barbell deadlift with 8RM (78% 1RM), 11RM (72% 1RM), and 16RM (65% 1RM) for 3 sets

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: There will be four conditions (three exercises and one control) on visits 3-6. For the three exercise conditions, all training parameters except intensity will be the same. The sets in high, moderate, and low intensity correspond to the rate of perceived exertion (0-10 scale) 7-9, 5-6, and 3-4, respectively. Therefore, the participants will perform 5 repetitions barbell squat, barbell press, and barbell deadlift with 8RM (78% 1RM), 11RM (72% 1RM), and 16RM (65% 1RM) for 3 sets

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: There will be four conditions (three exercises and one control) on visits 3-6. For the three exercise conditions, all training parameters except intensity will be the same. The sets in high, moderate, and low intensity correspond to the rate of perceived exertion (0-10 scale) 7-9, 5-6, and 3-4, respectively. Therefore, the participants will perform 5 repetitions barbell squat, barbell press, and barbell deadlift with 8RM (78% 1RM), 11RM (72% 1RM), and 16RM (65% 1RM) for 3 sets
Study: NCT05331014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LivaloVA
Description: For 8 weeks(PO, QD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LivaloV
Description: For 8 weeks(PO, QD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VA
Description: For 8 weeks(PO, QD)
Study: NCT04238390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane-Tazobactam
Description: Ceftolozane-tazobactam 3 grams (comprising ceftolozane 2 grams and tazobactam 1 gram) administered, every 8 hours, three times a day, intravenously over 60 mins. Dose adjusted for renal function.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Meropenem 1 gram, every 8 hours, three times a day, intravenously over 30 mins. Dose adjusted for renal function.
Study: NCT04740476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STK-001
Description: STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection.
Study: NCT04842201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM326
Description: subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection
Study: NCT06307912

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Video placebo communication
Description: The placebo communication video comprises of an educational VR video containing placebo enhancing verbal language.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video nocebo communication
Description: The nocebo communication video comprises of an educational VR video containing nocebo enhancing verbal language.
Study: NCT05517642

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)
Description: Subjects will be randomized to receive a second booster dose of IH Convidecia vaccine (treatment arm)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA vaccine BNT162b2 (Pfizer)
Description: Subjects will be randomized to receive a second booster dose of BNT162b2.
Study: NCT04755595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox Cosmetic Injectable Product
Description: Acetylcholine release inhibitor and a neuromuscular blocking agent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvéderm Voluma XC
Description: Gel implants consisting of cross-linked hyaluronic acid

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvéderm Volbella XC
Description: Gel implants consisting of cross-linked hyaluronic acid
Study: NCT06422793

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No NG tube gastric decompression
Description: Participants in this group will not undergo gastric decompression following orthognathic surgery at our institution.
Study: NCT05353829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: When accepted inclusion the patient will be included in SRQ, and thereafter randomised for Methotrexate per oral or subcutaneous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: When accepted inclusion the patient will be included in SRQ, and thereafter randomised for Methotrexate per oral or subcutaneous administration
Study: NCT05136937

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncolytic Virus Injection(RT-01)
Description: Administered by intratumoral injection for 3 dose cohorts: 1×10\^7 TCID50/mL, 1×10\^8 TCID50/mL and 7×10\^8 TCID50/mL
Study: NCT05166694

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug-Drug Interaction Profile
Description: A profile based on genetic testing that shows information about how the participant's medications they are taking interact with each other.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug-Drug Interaction Profile
Description: A profile based on genetic testing that shows information about how the participant's medications they are taking interact with each other.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug-Gene Interaction Profile
Description: A profile based on genetic testing that shows information about how the participant's genes interact with/respond to certain medications they are taking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: The standard treatment and prescribing for the participant's specific type of cancer.
Study: NCT05319392

Intervention type: DIAGNOSTIC_TEST
Intervention: Observational study
Description: Exploration of transcriptomic signatures related to tumor microenvironment having a significant role in prognosis of gastric adenocarcinoma patients
Study: NCT05079503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEN-001
Description: GEN-001, Lactobacillus lactis is a live, purified facultative anaerobic gram-positive probiotic lactic acid bacterial strain. GEN-001 is orally administered once daily during total TNT periods.
Study: NCT05979610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki therapy
Description: Reiki therapy is a form of energy healing that originated in Japan. It involves the transfer of energy from the Reiki practitioner to the recipient through the hands, with the goal of promoting physical, emotional, and spiritual well-being. Below is a general outline of the process of Reiki therapy, which may vary slightly depending on the needs of the recipient:~* The patient will be in a quiet clinic room lying in the supine position with calming music playing and aromatherapy if the patient chooses.~* The Reiki therapist will place their hands on or near the recipient's body. The Reiki therapist may use a series of hand positions that correspond to different energy centers in the body.~* During the treatment, the practitioner channels energy into the recipient's body through their hands. The patient may feel a sense of warmth, tingling, or relaxation.~* The Reiki therapist may use different techniques, such as hand movements or visualization.
Study: NCT06010966

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: intermittent theta-burst stimulation (iTBS)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: intermittent theta-burst stimulation (iTBS)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: intermittent theta-burst stimulation (iTBS)
Study: NCT05144607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Pressure curve (Pmus)
Description: The intervention will be the display of an additional curve - the estimated inspiratory muscle pressure waveform generated using an artificial intelligence algorithm.
Study: NCT05006885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Injected subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Injected subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Injected subcutaneously (SC)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injected subcutaneously (SC)
Study: NCT05313061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: MTX continuation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: MTX continuation
Study: NCT04737577

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supramarginal resection
Description: Tissue removal beyond the GAD-enhancing region extending to either at least 1 cm into non-enhancing tissue, or the nearest non-enhancing sulcal boundary/ventricle wall if these structures are closer than 1 cm.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional (i.e. GTR) resection
Description: Planned resection of ≥95% of the GAD-enhancing regions of tumor without expanding the resection beyond this margin.
Study: NCT05873244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zabadinostat (CXD101) and Geptanolimab
Description: * Zabadinostat (CXD101) at 20mg twice daily per orally Day 1-5 every 3 weeks~* Geptanolimab at 3mg/kg given intravenously every 2 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Lenvatinib and Sorafenib
Description: Clinicians' choice of TKI at corresponding recommended dosage:~* Lenvatinib at 8mg daily for patients with body weight \<60kg or 12mg daily with body weight ≥ 60kg~* Sorafenib at 400mg twice daily
Study: NCT04813471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endothelial Protocol
Description: Endothelial Protocol
Study: NCT04797143

Intervention type: DEVICE
Intervention: multidisciplinary consultation program
Description: The multidisciplinary consultation program (MCP) was divided into 3 steps: the first step involved a consultation with an oncologist, the second step involved a consultation with an oncology pharmacist, and the third step involved a meeting with a coordinating nurse (CN). The CN put in place a regular telephone follow-up with the patient, a few days later (7 to 15 days), to ensure adherence and tolerance of the oral anticancer treatment (OAT).
Study: NCT05053295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: autologous activated T lymphocyte
Description: Drug: Immuncell-LC IV~Drug: Nivolumab (Opdivo®) IV
Study: NCT06296862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Approaches to Stop Hypertension Diet
Description: The DASH diet is a heart-healthy eating pattern that is focused on adequate consumption of fruits, vegetables, whole grains, low-fat dairy, fish, poultry, beans, nuts, and vegetables oils while emphasizing limited intake of foods containing saturated fat, such as fatty red meats, full-fat dairy products, and tropical oils, such as coconut, palm kernel, and palm oils, as well as sugar-sweetened beverages and sweets. The chosen 4 week intervention duration phase is consistent with previous research showing positive effects of consuming a sodium-reduced dietary intervention on volume status and is longer than in other studies showing positive effects of DASH diet consumption on cardiac outcomes among HF patients. Potential carryover effects are minimized by a washout period of 4 weeks. The meal plan has been previously developed based on NHLBI guidelines for the DASH diet.
Study: NCT05229146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking
Description: Episodic future thinking (EFT) includes a focus on generating detailed and vivid descriptions of future events. For the current intervention, EFT will be modified to have mothers describe specific events with their children.
Study: NCT05150379

Intervention type: OTHER
Intervention: Different exercises with their shoulders
Description: * Y Balance Test~* Shoulder rotator muscle isometric maximum strength~* One handed medicine ball throw~* Modified Closed Kinetic Chain Upper Extremity Stability Test

Intervention type: OTHER
Intervention: Different exercises with their shoulders
Description: * Y Balance Test~* Shoulder rotator muscle isometric maximum strength~* One handed medicine ball throw~* Modified Closed Kinetic Chain Upper Extremity Stability Test

Intervention type: OTHER
Intervention: Different exercises with their shoulders
Description: * Y Balance Test~* Shoulder rotator muscle isometric maximum strength~* One handed medicine ball throw~* Modified Closed Kinetic Chain Upper Extremity Stability Test

Intervention type: BEHAVIORAL
Intervention: SI-RSI questionnaire
Description: French version of Shoulder Instability Return-to-Sport after Injury

Intervention type: BEHAVIORAL
Intervention: SI-RSI questionnaire
Description: French version of Shoulder Instability Return-to-Sport after Injury

Intervention type: BEHAVIORAL
Intervention: SI-RSI questionnaire
Description: French version of Shoulder Instability Return-to-Sport after Injury
Study: NCT05044208

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG monitoring
Description: After clinical routine diagnostics an additional ambulatory ECG monitoring for 7 days is established

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG monitoring
Description: After clinical routine diagnostics an additional ambulatory ECG monitoring for 7 days is established
Study: NCT04622007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tomivosertib
Description: Tomivosertib (eFT508) will be taken at 100 mg twice daily (bid) with meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tomivosertib
Description: Tomivosertib (eFT508) will be taken at 100 mg twice daily (bid) with meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tomivosertib
Description: Tomivosertib (eFT508) will be taken at 100 mg twice daily (bid) with meals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Subjects will initiate or continue to receive pembrolizumab at either 200 mg intravenously (IV) at a frequency of every 3 weeks or 400 mg IV at a frequency of every 6 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Subjects will initiate or continue to receive pembrolizumab at either 200 mg intravenously (IV) at a frequency of every 3 weeks or 400 mg IV at a frequency of every 6 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Subjects will initiate or continue to receive pembrolizumab at either 200 mg intravenously (IV) at a frequency of every 3 weeks or 400 mg IV at a frequency of every 6 weeks.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab
Description: Subjects will initiate or continue to receive pembrolizumab at either 200 mg intravenously (IV) at a frequency of every 3 weeks or 400 mg IV at a frequency of every 6 weeks.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab
Description: Subjects will initiate or continue to receive pembrolizumab at either 200 mg intravenously (IV) at a frequency of every 3 weeks or 400 mg IV at a frequency of every 6 weeks.
Study: NCT06370819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: NNC0519-0130 will be administered subcutaneously.
Study: NCT06222346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CommonGround
Description: Through collaboration with people living with LTCs, clinicians, academics, and web design experts, we have co-designed an online peer support and psychoeducation platform to help people with physical health conditions connect, support others, share experiences, and receive evidence-based information and advice on self-management. The web-based platform offers users access to peer support forums with embedded psychoeducation content.~The following components are key features of the platform:~* A discussion forum~* A private My Garden page that stores posts from other users and psychoeducation content that the user has decided to 'save'.~* A resources page giving access to evidence-based psychoeducation material on the mind-body link~* A 'Crisis and Further Support' page, where users can find further organisations and sources of support, particularly for crisis situations. The peer support platform does not offer one-to-one or crisis support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NHS Mental Health
Description: Participants in the control arm will be directed towards the Mental Health webpage(s), an online resources page provided by the NHS. These resources are not specifically targeted at people living with LTCs. They include information sheets and mental health support on topics such as advice for life situations and events. Additionally, it hosts a self-help section that includes guides, tools, and activities to support mental health, but does not include any interactive or peer support elements.
Study: NCT06381713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensive combined phonetic-phonological intervention
Description: Children will receive phonetic articulation therapy supplemented by phonological principles. Consonants will be treated with emphasis on phonetic placement and shaping techniques. Phonetic articulation therapy includes five different steps:(1) identification of the target consonant using visual, tactile, and auditory feedback techniques,(2) discrimination between the used and targeted consonant, (3) variation and correction, (4) stabilize the target, and (5) maintenance of the target. A next level will be introduced when the child is able to correctly produce the sound in 80% of the time with minimal cues from the therapist. Multiple errors will be targeted simultaneously by focusing on a process. Child-friendly games will be played to illustrate the contrast between concepts, for example glottal 'throat' sounds and oral 'mouth' sounds. Exercises will be embedded in meaningful language contexts such as minimal pairs.~Therapy will be provided 5 times 30' per week for 2 times 4 weeks.
Study: NCT04622007

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab
Description: Subjects will initiate or continue to receive pembrolizumab at either 200 mg intravenously (IV) at a frequency of every 3 weeks or 400 mg IV at a frequency of every 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Subjects will initiate pemetrexed at 500 mg/m2 intravenously (IV) at a frequency of every 3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: Subjects will initiate pemetrexed at 500 mg/m2 intravenously (IV) at a frequency of every 3 weeks.
Study: NCT05910866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left bundle branch area pacing (LBBAP)
Description: Pacing of the conduction system of the heart to obtain physiological activation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Right ventricular pacing (RVP)
Description: Conventional ventricular pacing
Study: NCT04052659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200 mg IV, every 3 weeks, d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 30 mg PO, 2 times every week, d1 and d4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacidine
Description: 100 mg SC, every 3 weeks, d1 to d7
Study: NCT01109888

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrotide
Study: NCT05224583

Intervention type: PROCEDURE
Intervention: Simultaneous Liver-Kidney Transplant
Description: Simultaneous Liver-Kidney Transplant